A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes

Inclusion Criteria:

- Have type 2 diabetes, treated with diet and exercise, with or without metformin and/or
basal insulin. Metformin and/or basal insulin dose must be stable for at least 8 weeks
prior to study screening.

- Have HbA1c >6.5% to ≤11% at screening visit. If newly diagnosed and not on medicine
for diabetes, HbA1c must be between >6.5 % to ≤9%.

- Have a BMI (body mass index) >85 percentile for age, gender and body weight ≥50
kilograms (110 pounds).

Exclusion Criteria:

- Known type 1 diabetes, or positive GAD65 or IA2 antibodies, or history of diabetic
ketoacidosis after taking diabetes medication.

- A history of, or at risk for pancreatitis.

- Self or family history of Multiple Endocrine Neoplasia (MEN) type 2A or B, thyroid
C-cell hyperplasia or medullary thyroid cancer, or a blood calcitonin result ≥20
picograms per milliliter (pg/ml) at screening.

- A systolic blood pressure of ≥160 millimeters of mercury (mmHg) or diastolic ≥100mmHg.

- Active or treated cancer.

- A blood disorder where an accurate HbA1c may not be obtainable.

- A female of childbearing age, sexually active and not on birth control.

- Pregnant or plan to be pregnant during the study, or breastfeeding.

- Taking any diabetic medication other than metformin or basal insulin and have not
stopped it 3 months prior to the screening visit.

- Have taken oral steroids within the last 60 days or more than 20 days use within the
past year or 1000 micrograms fluticasone propionate per day.

- Using prescription weight loss medications in the last 30 days, or plan to use.

- Taking psychiatric medications for depression or illness or attention deficit
hyperactivity disorder (ADHD) if, the doses has changed within the last 3 months.